TBCE and Hepatic steatosis: Drug-encapsulated liposome administration has been utilized to selectively deplete KCs and visceral adipose tissue macrophages (VATMs) to improve glucose and insulin sensitivity and reduce hepatic steatosis in DIO mouse models [12], [16], [17].